LIC are protected from conventional chemotherapy by their BM microenvironment and we have previously shown that CD34+ LIC in FLT3-ITD AML persist and expand during treatment with first- and second generation TKI owing to their selective protection by stromal cells [9]. This evidence concerns the gene FLT3 and acute myeloid leukemia.